HK1205107A1 - 咪唑酮類衍生物、其藥物組合物和用途 - Google Patents

咪唑酮類衍生物、其藥物組合物和用途

Info

Publication number
HK1205107A1
HK1205107A1 HK15105457.8A HK15105457A HK1205107A1 HK 1205107 A1 HK1205107 A1 HK 1205107A1 HK 15105457 A HK15105457 A HK 15105457A HK 1205107 A1 HK1205107 A1 HK 1205107A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
imidazolone derivatives
imidazolone
derivatives
pharmaceutical
Prior art date
Application number
HK15105457.8A
Other languages
English (en)
Inventor
張興民
季奇
王磊
高聰敏
王恩思
杜鎮建
鞏龍龍
陳博
Original Assignee
Beijing Forelandpharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Forelandpharma Co Ltd filed Critical Beijing Forelandpharma Co Ltd
Publication of HK1205107A1 publication Critical patent/HK1205107A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15105457.8A 2013-11-20 2015-06-09 咪唑酮類衍生物、其藥物組合物和用途 HK1205107A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310589080 2013-11-20

Publications (1)

Publication Number Publication Date
HK1205107A1 true HK1205107A1 (zh) 2015-12-11

Family

ID=52894558

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105457.8A HK1205107A1 (zh) 2013-11-20 2015-06-09 咪唑酮類衍生物、其藥物組合物和用途

Country Status (8)

Country Link
US (1) US10047084B2 (zh)
EP (1) EP3072893B1 (zh)
JP (1) JP6290412B2 (zh)
CN (1) CN104447740B (zh)
AU (1) AU2014352463B2 (zh)
CA (1) CA2931147C (zh)
HK (1) HK1205107A1 (zh)
WO (1) WO2015074516A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931147C (en) 2013-11-20 2018-05-29 Beijing Forelandpharma Co. Ltd. Imidazolone derivatives, pharmceutical compositions and uses thereof
CN106995441B (zh) * 2016-01-26 2019-05-21 北京富龙康泰生物技术有限公司 咪唑酮类化合物的晶型、其制备方法、药物组合物和用途
US10646483B2 (en) * 2016-01-26 2020-05-12 Foreland Pharma Co., Ltd. Crystal form of imidazolone type compounds, and preparation method, pharmaceutical composition and use thereof
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370508B2 (en) 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EA020715B1 (ru) * 2009-06-04 2015-01-30 Новартис Аг ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
SG179085A1 (en) * 2009-09-09 2012-04-27 Avila Therapeutics Inc Pi3 kinase inhibitors and uses thereof
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
MX2013006284A (es) * 2010-12-06 2013-10-28 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina.
CN103833752A (zh) 2012-11-20 2014-06-04 北京富龙康泰生物技术有限公司 咪唑酮并喹啉类衍生物、其药物组合物和用途
CA2931147C (en) 2013-11-20 2018-05-29 Beijing Forelandpharma Co. Ltd. Imidazolone derivatives, pharmceutical compositions and uses thereof

Also Published As

Publication number Publication date
US20160304510A1 (en) 2016-10-20
US10047084B2 (en) 2018-08-14
AU2014352463A1 (en) 2016-06-02
CA2931147C (en) 2018-05-29
CN104447740B (zh) 2017-02-22
AU2014352463B2 (en) 2017-05-11
EP3072893B1 (en) 2020-03-18
CA2931147A1 (en) 2015-05-28
JP6290412B2 (ja) 2018-03-07
CN104447740A (zh) 2015-03-25
WO2015074516A1 (zh) 2015-05-28
EP3072893A1 (en) 2016-09-28
JP2016537393A (ja) 2016-12-01
EP3072893A4 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
IL243042A0 (en) Consequences of aminotriazine and a pharmaceutical preparation containing it
IL240290B (en) History of pyridazinone-amide and pharmaceutical preparations containing them
PL2943181T3 (pl) Kompozycje farmaceutyczne
HK1222563A1 (zh) 藥物組合物、製備及其用途
ZA201408333B (en) Pharmaceutical compositions
HK1211021A1 (zh) -取代- -聯芳基甲基氨基- -環戊基- -嘌呤衍生物、其作為藥物的用途及藥物組合物
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
HK1205107A1 (zh) 咪唑酮類衍生物、其藥物組合物和用途
HK1219691A1 (zh) 醫藥組成物及其用途
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
IL243223B (en) History of imidazole, their preparation and pharmaceutical preparations containing them
IL238851A0 (en) The history of pyrrolidine, pharmaceutical preparations and their uses
ZA201601645B (en) Bendamustine pharmaceutical compositions
IL239873A0 (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
HRP20171888T1 (hr) Farmaceutski pripravci
IL284405A (en) Pharmaceutical composition, preparation and uses thereof
GB201304699D0 (en) Pharmaceutical compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions